Form D · Pharmaceuticals

Fuse Biotherapeutics, Inc.

Los Angeles, CA · CIK 0001871839

Offering snapshot reported Nov 12, 2021 · SEC filing

Reported sold
$8.18M
Offering amount: $9.57M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 24, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$4.09M$8.18MJul 9, 2021: $2,624,997.00Jul 9, 2021Nov 12, 2021: $8,184,630.00Nov 12, 2021: $8,184,630.00Nov 12, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$2,624,997 → $8,184,630

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 12, 2021Amendment$8,184,630$5,559,633vs Jul 9, 20218SEC filing
Nov 12, 2021Amendment$8,184,630$5,559,633vs Jul 9, 20218SEC filing
Jul 9, 2021Initial$2,624,997No comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-405726

Source: Form D, filed Nov 12, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Yuanheng Wang Liang Director
Brian Rabinovich Director, Executive
Paul Song Director, Executive
Jeffrey Takimoto Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
6080 Center Drive 6 Th Floor
Los Angeles, CA, 90045